Abstract
Although the application of human mesenchymal stem cells (hMSCs) to repair damaged or diseased tissues has proven relatively effective, both the donor-to-donor variability in ex vivo expansion rates and the maintenance of stemness remain a bottleneck to widespread translation. Previous work from this laboratory stratified donors into those yielding hMSCs with high- or low-growth capacity; global transcriptomic analysis revealed that high-growth-capacity hMSCs were characterized by a loss of the gene encoding glutathione S-transferase theta 1 (GSTT1). These GSTT1-null hMSCs demonstrated increased proliferative rates, clonogenic potential, and longer telomeres compared with low-growth capacity hMSCs that were GSTT1-positive. Thus, this study identifies GSTT1 as a novel genomic DNA biomarker for hMSC scalability.
Funding Information
  • National Medical Research Council (OFIRG16May119)
  • Agency for Science, Technology and Research
  • Institute of Medical Biology
  • National Medical Research Council (OFIRG16May119)
  • Agency for Science, Technology and Research
  • Institute for Mind and Body, University of Chicago

This publication has 59 references indexed in Scilit: